

Administra	ative				
☑ Dr		/assume MRP			
Allergies or hy	ypersensitivities?	o ☐ Yes	s: (list)		
☑ MRSA scr	eening and clinical manage	ement protocol			
Monitoring	g				
⊠ Weight:		kg	□ actual	☐ estimate	
☐ Height:		cm	☐ actual	☐ estimate	
	s cardiac/SpO ₂ monitoring				
	e, respiratory rate, blood pr	essure (arterial w	here possible) q1h	and PRN	
☐ Intake and		l bladdar aantral	l von eue er erteriel	cothotor) ath and DDN	
Core temp	erature (esophageal, recta	i, biadder, central	i venous or arterial	cameter) q4m and PKN	
Tubes/Lin	es				_
Naso/Oroga	astric Tube				
☑ If not using	g for nutritional support, Na	sogastric tube or	Orogastric tube to	straight drainage	
Urinary Cat	heter				
□ Urinary ca	theter to urometer				
Intervention	ons				
☐ For all pote	ential kidney donors, maint	ain core temperat	ture between 34.0 a	and 35.0 degrees Celsius (stop if kid	dney donation
*	Ontario Health [TGLN])				
-	•	o Health (TGLN)	 warming blanket 	to maintain core temperature between	een 35.5 degrees
	7.0 degrees Celsius ri-Lube [®] or alternative ophtl	halmia lubriaant ta	a both over a? 4b		
		namic lubricant to	both eyes q2-411		
	ed elevated at 35 – 45 degr	ees (as tolerated)		
Laborator	y Investigations				
Initial Inves	=				
	•	ocyte Antigen (co	nsult with Ontario H	lealth (Trillium Gift of Life Network)	[TGLN])
	Ontario Health (TGLN) will				
• [Draw prior to fluid bolus and	d/or transfusion if	possible		
Blood Bank	(
☐ Group+Sc	reen				
_	• .	• • •	st be requested (cor	nsult with Ontario Health [TGLN])	
	s (as below) to be done q	6h and PRN			
	y and Coagulation				
⊠ CBC	⊠ INR				
ID	PRINTED NAME		YYY-MM-DD HH:MM	□ Read Back	
	· ···· <u>-</u>				
ID	PRINTED NAME		YYY-MM-DD HH:MM	SIGNATURE	-



Submitted by:



Laboratory Inv	estigations Co	ntinued				
Chemistry						
⊠ Electrolytes						
☐ Creatinine	□ Lactate □					
☐ Glucose		cium, Phosphate				
Toxicology						
Serum and	urine toxicology scre	en for all patients except if possibility	of overdose ruled out by MD or previously done			
☐ Serum toxicolog	y screen (if indicated	I by admission history or previous res	ults)			
☐ Urine toxicology	screen					
Supplemental	Laboratory Inve	estigations				
Activated Partia	l Thromboplastin Tim	ne (aPTT) NOW and PRN				
□ Protein (Total) ■	NOW and PRN					
Amylase NOW	and PRN					
	C NOW					
□ Capillary glucos	e monitoring PRN an	d as per hospital policy/procedure				
☑ Blood Urea Nitro	ogen NOW and PRN					
□ Urinalysis NOW						
		pe 2 diabetes-urine albumin to creati				
		orm urine albumin to creatinine ratio t tinine ratio NOW and PRN	est AND patient known to have Type 1 or Type 2			
•••	•••	rine and sputum cultures must Canada requirements.	be completed within 24 hours of organ			
	nd Sensitivity (C+S) (two different sites) NOW and PRN				
Sputum C+S NO	DW and PRN (initial s	sample NOT required IF BAL C&S co	mpleted)			
☐ Urine C+S NOV	and PRN (minimum	of ONE urine culture is required by H	Health Canada for all potential organ donors,			
regardless of urinal	ysis results)					
Additional Lab	Orders					
<u> </u>						
Hemodynamic	Monitoring and	l Therapy Targets				
Blood pressure ind	ices:					
 Heart 	rate greater than or e	equal to 60 beats/minute and less that	n or equal to 120 beats/minute			
 Systolic blood pressure (SBP) greater than or equal to 100 mmHg and less than or equal to160 mmHg 						
• Mean	 Mean arterial blood pressure (MAP) greater than or equal to 65 mmHg 					
Note: Maintain Hemoglobin greater or equal to 70 g/L						
Cardiovascula	r Management					
☐ 12-lead ECG x	1 NOW and PRN					
☐ Insert a subclav	ian or jugular central	line				
☐ 2D echocardiogram NOW (see Associated Documents)						
☐ Cardiac angiogram* As per direction from Ontario Health (TGLN)						
ID P	RINTED NAME	YYYY-MM-DD HH:MM	☐ Read Back			
	_	· · ······ == · · · ······				
ID P	RINTED NAME	YYYY-MM-DD HH:MM	SIGNATURE			

Submitted by:



Exact dosing for each medication to be calculated and individualized

Hypotension Management (Use Mean Arterial Pressure (MAP) unless arterial monitoring unavailable or unreliable)					
☑ IV Ringer's Lactate 500ml over 10 minutes PRN if SBP less than 100mmHg or MAP less than 65 mmHg					
☑ Vasopressin IV infusion at 0.1 – 2.4 units/h PRN for SBP less than 100 mmHg or MAP less than 65 mmHg					
☐ Norepinephrine IV infusion at 1 – 30 micrograms/minute PRN for SBP less than 100 mmHg or MAP less than 65 mmHg					
☐ Epinephrine IV infusion at 1 – 20 micrograms/minute PRN for SBP les than 100 mmHg or MAP less than 65 mmHg					
Hypertension Management (Use MAP unless arterial monitoring unavailable or unreliable)					
ype a sign a					
Wean inotropes or vasopressors if infusing; start antihypertensives for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg					
☐ Hydralazine 10 – 20 mg IV q4h PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg					
☐ Nitroglycerin IV infusion at 5 – 200 micrograms/minute PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg					
☐ Labetalol IV infusion at 1 – 2 mg/min PRN for SBP greater than 160 mmHg and/or MAP greater than 90 mmHg (discontinue if					
HR less than 65)					
☐ Esmololmicrograms/kg/min IV bolus (100 – 500 micrograms/kg IV bolus; consider reduced dose in the elderly					
population) followed by Esmolol 100 – 300 micrograms/kg/minute IV infusion PRN for SBP greater than 160 mmHg and/or MAP					
greater than 90 mmHg					
Mechanical Ventilation Targets					
 Tidal volume measurements: Tidal volume (V₁) 6 − 8 mL/kg 					
 PEEP: Positive End Expiratory Pressure 8-10 cm H₂O 					
 PIP: Peak Inspiratory Pressure less than or equal to 30 cm H₂O 					
Respiratory Management					
☐ Chest x-ray (CXR) q12h and PRN (coordinate to perform post-recruitment maneuver-see below)					
☐ Bronchoscopy and Bronchial Alveolar Lavage (BAL): Gram Stain and C+S x 3 (separate samples from each lung and 1 sample					
for Ontario Health [TGLN] COVID requirements) and PRN (see Associated Ontario Health [TGLN] Document)					
☐ Routine ETT suctioning as tolerated q2h and PRN					
Salbutamol 8 puffs q2 − 4h PRN for wheezing					
☐ Ipratropium 8 puffs q2-4h PRN for wheezing					
Recruitment Maneuvers					
Target to maintain normalized arterial blood gases: pH 7.35 – 7.45, PaCO ₂ 35 – 45 mmHg, PaO ₂ greater or equal to 80 mmHg, O ₂ sat greater than or equal to 95%					
☐ For all potential lung donors: In the following sequence, perform recruitment maneuvers and challenge arterial blood gases					
(ABG) q6h as tolerated. (stop if lung donation excluded by Ontario Health [TGLN], recruitment manoeuvers not tolerated or as					
dictated by patient status)					
Perform the following recruitment maneuvers in sequence:					
 Pre-oxygenate with FiO₂ of 1.0 for 10 minutes 					
 Sustained inflation with PEEP of 30 cm H₂O for 30 seconds 					
Maintain FiO ₂ of 1.0 and return to maintenance ventilatory parameters					
Draw ABG 10 minutes post inflation (while FiO ₂ at 1.0)					
• Return to maintenance FiO ₂ once complete					
Obtain chest x-ray once completed					
☐ If lung recruitments not tolerated – ABG on Fi02 1.0 q6h and PRN on and PRN					
☐ If lung donation excluded by Ontario Health (TGLN) — stop lung recruitment maneuvers and continue ABG and CXR as per unit					
protocols					
☐ Read Back					
ID PRINTED NAME YYYY-MM-DD HH:MM					

YYYY-MM-DD HH:MM

SIGNATURE

Ontario Health
Trillium Gift of Life Network

PRINTED NAME

Submitted by:



Fluid and Electrolyte Targets

- Urine output 0.5 3 mL/kg/h (if urine output below 0.5 cc/hr OR urine output above 300 cc/hr consult MRP)
- Serum sodium equal to or above 130 mmol/L and equal to or below 150 mmol/L
- Normal ranges for potassium, calcium, magnesium, and phosphate

	glucose 6 – 10 mmol/L	iesium, and phosphate	•
Fluid and El	ectrolytes		
i idid dila Li	-	modication to be calcu	lated and individualized***
M Bingara Last	•	medication to be calcu	lated and individualized***
-	ate IV infusion for maintenance at	hataa laainidua (aaa a	mL/h
	um above145 mmol/L evaluate for Dia		
	plement hospital standing order set for	•	
protoc		men administer socium	n phosphate 15 mmol in 100 mL D5W IV as per unit
☐ If o	corrected serum calcium below 2.0 mm	ol/L or ionized Ca less	than 1.0 mmol/L, then administer 10% calcium
gluco	nate 1 gram in 100 mL NaCl or D5W I	over 30 minutes (cent	tral or peripheral)
☐ If s	serum magnesium below 0.8 mmol/L, t	hen administer magnes	sium sulphate 1 g in 50 – 100 mL NaCl or D5W IV over
30 mi	nutes (central or peripheral)		
☐ If p	ootassium below 3.9 mmol/L and great	er than 3.2 mmol/L, the	en administer 20 mmol potassium chloride in 50 – 100
mL Na	aCl or D5W via central line over 1 hour		
☐ If s	serum potassium below 3.2 mmol/L, th	en administer 40 mmol	potassium chloride in 100 mL NaCl or D5W via central
	ver 2 hours		
	DO NOT ADMINISTE	R HYDROXYETHYL S	TARCH e.g. VOLUVEN
Glycemic ar	nd Nutrition Management		_
-	ntinue nutritional support, when approp	riate and possible	
	to planned OR stop enteral feeds and	·	s then clamp NG tube
	trate insulin infusion to maintain serum		,
Endocrine a	nd Metabolic Management		_
	Exact dosing for each	medication to be calcu	lated and individualized
For all potential	heart donors administer (Stop if heart		
	00 micrograms IV x 1, then L-thyroxin		
OR The state of	Notice and the first of the second PO Asiles		
☐L-Thyroxine 2	micrograms/kilogram PO daily		
□ For all potent	tial lung donors – methylprednisolone	15 mg/kg (maximum 1	g) IV q24h (Stop if lung donation excluded by Ontario
Health [TGLN])			
☑ If lung donati	on excluded by Ontario Health (TGLN) AND patient requiring	vasopressors then administer hydrocortisone 50 mg
IV q6h			
	ntinue hospital insulin infusion order se	t to maintain serum glu	icose 6-10 mmol/L
If creatinine of the control of the contro	clearance less than 60 mL/min, kidney	s have NOT been ruled	out for transplant and IV contrast is planned, give IV
0.9% NaCl 3 mL	/kg/h for 3 hours pre-contrast then 1 n	nL/kg/h for 6 hours pos	t-contrast
ID	PRINTED NAME	YYYY-MM-DD HH:MM	☐ Read Back
10	I NATED IVANIE	THE LEWING DOCUMENTS	
ID	PRINTED NAME	YYYY-MM-DD HH:MM	SIGNATURE



Submitted by:



Diabetes Insipidus Targets

· Titrate therapy to urine output of les than or equal to 3 mL/kg/h

Diabetes Insipidus Management

Clinical Indicators of Diabetes Insipidus

- · Urine output greater than 4 mL/kg/h, and
- · Rising serum sodium and/or
- · Sodium greater than or equal to145 mmol/L and/or
- · Rising serum osmolarity greater than or equal to 300 mosM and/or
- Decreasing urine osmolarity less than or equal to 200 mosM
- · Specific Gravity less than 1.010

Diabetes	Insipidus	Therapy
----------	-----------	---------

*** = ~ ~ ~ +	dooina	for oooh	modioation	+0 h	a adjouted	and	individualize	~**:
Exact	aosina	roi eacii	medication	TO D	e calculated	anu	muividualize	u

☐ If Vasopressin initiated for diabetes insipidus, maintain a minimum dose of 0.5 units/hour to avoid polydipsia. If patient becomes						
nypertensive, consult with Ontario Health (TGLN) for management.						
☐ DDAVP 4 micrograms IV q6h PRN						
☐ If serum sodium greater than 145 mmol/L give enteral free H ₂ O 200 mL q4h and change maintenance IV to:						
□ 0.45% NaCl OR □ D5W						

References

- Ball, I.M., Hornby, L., Rochwerg, B., Weiss, M.J., Gillrie, C., Chassé, M., et al. (2020). Management of the neurologically deceased organ donor: A Canadian clinical practice guideline. CMAJ, April 06, 2020 192 (14) E361-E369; DOI: https://doi.org/10.1503/cmaj.190631
- Canadian Council for Donation and Transplantation. (2004). Medical management to optimize donor organ potential: A Canadian forum: Report and recommendations. February 23-25, 2004, Mont Tremblant, P.Q.
- Frontera, J.A., & Kalb, T. (2010). How I manage the adult potential organ donor: donation after neurological death (Part 1). *Neurocritical Care*, 12, 103-110.
- Mascia, L., Pasero, D., Slutsky, A.S., Arguis, M., J., Berardino, M., Grasso, S., et al. (2010). Effect of lung protective strategy for organ donors on eligibility and availability of lungs for transplant. *Journal of the American Medical Association*, 304(23), 2620-2627.
- Nice Sugar Study Investigators. (2009). Intensive versus conventional glucose control in critically ill patients. *The New England Journal of Medicine*, 360 (13), 1283-1297.

Submitted by:	ID	PRINTED NAME	YYYY-MM-DD HH:MM	□ Read Back
Practitioner:				
	ID	PRINTED NAME	YYYY-MM-DD HH:MM	SIGNATURE







Submitted by:				☐ Read Back
	ID	PRINTED NAME	YYYY-MM-DD HH:MM	
Practitioner:				
·	ID	PRINTED NAME	YYYY-MM-DD HH:MM	SIGNATURE

